A platform for NK and CAR-NK development
Five integrated modules connecting cell source strategy through to regulatory-ready advanced therapy products.
Cell Source Strategy
Cord blood and CD34+ progenitor-derived NK concepts evaluated for scalability, identity, and translational viability. Public information only — proprietary process parameters are not disclosed.
NK Expansion & Differentiation
Scalable development of NK cell products designed to support batch consistency, potency, and product comparability across development stages.
CAR-NK Engineering
Engineered NK cells expressing chimeric antigen receptors to enhance tumor recognition. Target selection, construct design, safety logic, comparability, potency, persistence, and off-target risk are subject to rigorous validation.
Cryopreservation & Logistics
Off-the-shelf readiness through validated cryopreservation, viability and potency preservation, traceability, chain of identity and chain of custody, and qualified cold-chain logistics.
Translational & Regulatory Package
CMC, identity, purity, potency, viability, safety, sterility, adventitious agent testing, comparability, stability, pharmacovigilance and long-term follow-up planning — with awareness of ANVISA, EMA and FDA frameworks.
From NK biology to a regulated advanced therapy product.
Each module is designed to feed forward into the next, with comparability, potency, and quality built in from discovery through clinical evaluation. Public information is intended for scientific and business-development purposes; proprietary methods and process parameters are not disclosed.